Literature DB >> 15240680

Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3',5'-monophosphate and phosphatases.

Hong Zhang1, David M Conrad, Jared J Butler, Chuanli Zhao, Jonathan Blay, David W Hoskin.   

Abstract

Adenosine is a purine nucleoside with immunosuppressive activity that acts through cell surface receptors (A(1), A(2a), A(2b), A(3)) on responsive cells such as T lymphocytes. IL-2 is a major T cell growth and survival factor that is responsible for inducing Jak1, Jak3, and STAT5 phosphorylation, as well as causing STAT5 to translocate to the nucleus and bind regulatory elements in the genome. In this study, we show that adenosine suppressed IL-2-dependent proliferation of CTLL-2 T cells by inhibiting STAT5a/b tyrosine phosphorylation that is associated with IL-2R signaling without affecting IL-2-induced phosphorylation of Jak1 or Jak3. The inhibitory effect of adenosine on IL-2-induced STAT5a/b tyrosine phosphorylation was reversed by the protein tyrosine phosphatase inhibitors sodium orthovanadate and bpV(phen). Adenosine dramatically increased Src homology region 2 domain-containing phosphatase-2 (SHP-2) tyrosine phosphorylation and its association with STAT5 in IL-2-stimulated CTLL-2 T cells, implicating SHP-2 in adenosine-induced STAT5a/b dephosphorylation. The inhibitory effect of adenosine on IL-2-induced STAT5a/b tyrosine phosphorylation was reproduced by A(2) receptor agonists and was blocked by selective A(2a) and A(2b) receptor antagonists, indicating that adenosine was mediating its effect through A(2) receptors. Inhibition of STAT5a/b phosphorylation was reproduced with cell-permeable 8-bromo-cAMP or forskolin-induced activation of adenylyl cyclase, and blocked by the cAMP/protein kinase A inhibitor Rp-cAMP. Forskolin and 8-bromo-cAMP also induced SHP-2 tyrosine phosphorylation. Collectively, these findings suggest that adenosine acts through A(2) receptors and associated cAMP/protein kinase A-dependent signaling pathways to activate SHP-2 and cause STAT5 dephosphorylation that results in reduced IL-2R signaling in T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240680     DOI: 10.4049/jimmunol.173.2.932

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis.

Authors:  Zoltán H Németh; Balázs Csóka; Jeanette Wilmanski; Dazhong Xu; Qi Lu; Catherine Ledent; Edwin A Deitch; Pál Pacher; Zoltán Spolarics; György Haskó
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

Authors:  Li Liu; Jui-Hung Yen; Doina Ganea
Journal:  Peptides       Date:  2007-03-31       Impact factor: 3.750

3.  Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function.

Authors:  Balázs Csóka; Leonóra Himer; Zsolt Selmeczy; E Sylvester Vizi; Pál Pacher; Catherine Ledent; Edwin A Deitch; Zoltán Spolarics; Zoltán H Németh; György Haskó
Journal:  FASEB J       Date:  2008-07-14       Impact factor: 5.191

Review 4.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

5.  Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function.

Authors:  C T Burton; S J Westrop; I Eccles-James; A Boasso; M R Nelson; M Bower; N Imami
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 6.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

Review 7.  Purinergic regulation of the immune system.

Authors:  Caglar Cekic; Joel Linden
Journal:  Nat Rev Immunol       Date:  2016-03       Impact factor: 53.106

Review 8.  Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.

Authors:  Magis Mandapathil; Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2011-06-26       Impact factor: 4.388

Review 9.  The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.

Authors:  Nick van Dijk; Samuel A Funt; Christian U Blank; Thomas Powles; Jonathan E Rosenberg; Michiel S van der Heijden
Journal:  Eur Urol       Date:  2018-09-28       Impact factor: 20.096

Review 10.  Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes).

Authors:  Theresa L Whiteside
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.